Opinion

Video

Evolving Treatment Paradigms in Ph+ ALL

Dr. Bijal Shah explores the recent advancements and shifts in treatment strategies for Ph+ ALL, driven by innovations in targeted therapies and evolving clinical practices

  • How has the treatment approach for Ph+ ALL evolved in recent years?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
4 experts in this video
4 experts in this video
Related Content
FDA approval | Image Credit: Tada Images - stock.adobe.com .jpeg
September 13th 2025

5 First-in-Class, First-in-Disease FDA Approvals From August

Brooke McCormick
managed care cast logo
September 13th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM
Man rubbing wrist | Image credit: pikselstock - stock.adobe.com
September 13th 2025

Individuals With HIV Have an Increased Risk of Osteoporosis

Julia Bonavitacola
managed care cast logo
September 13th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
September 13th 2025

Survival Outcomes in Advanced NSCLC Improved With Use of Cemiplimab

Julia Bonavitacola
Atopic Dermatitis | Image Credit: © slobodyan_78-stock.adobe.com
September 13th 2025

Biomarker Insights Differentiate JAK1 vs IL-13 Therapy in AD

Maggie L. Shaw

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo